 Lays Martin Sobral
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 7 | 2020 | 79 | 1.450 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2020 | 610 | 1.300 |
Why?
| | Histone Chaperones | 5 | 2020 | 14 | 1.230 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 2 | 2020 | 59 | 0.830 |
Why?
| | Fibroblasts | 9 | 2011 | 842 | 0.720 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 356 | 0.550 |
Why?
| | Antineoplastic Agents | 5 | 2020 | 1974 | 0.470 |
Why?
| | Cell Proliferation | 10 | 2020 | 2275 | 0.450 |
Why?
| | Myofibroblasts | 3 | 2011 | 120 | 0.440 |
Why?
| | Transcription Factors | 3 | 2017 | 1570 | 0.430 |
Why?
| | Head and Neck Neoplasms | 3 | 2017 | 471 | 0.420 |
Why?
| | DNA-Binding Proteins | 5 | 2020 | 1346 | 0.390 |
Why?
| | Gingiva | 4 | 2011 | 22 | 0.380 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 32 | 0.370 |
Why?
| | Stromal Cells | 5 | 2011 | 102 | 0.360 |
Why?
| | Peptides | 2 | 2020 | 879 | 0.350 |
Why?
| | Activins | 2 | 2015 | 26 | 0.340 |
Why?
| | Smad7 Protein | 3 | 2011 | 26 | 0.320 |
Why?
| | MicroRNAs | 2 | 2020 | 637 | 0.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1167 | 0.300 |
Why?
| | Mouth Mucosa | 3 | 2017 | 82 | 0.300 |
Why?
| | Gingival Overgrowth | 2 | 2011 | 5 | 0.300 |
Why?
| | Cyclosporine | 2 | 2011 | 173 | 0.280 |
Why?
| | Keratinocytes | 1 | 2017 | 227 | 0.270 |
Why?
| | Matrix Metalloproteinase 2 | 3 | 2011 | 56 | 0.270 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 539 | 0.270 |
Why?
| | Histones | 1 | 2020 | 552 | 0.260 |
Why?
| | Neoplasms | 1 | 2019 | 2179 | 0.250 |
Why?
| | Cell Survival | 6 | 2020 | 1047 | 0.250 |
Why?
| | Doxorubicin | 1 | 2015 | 302 | 0.240 |
Why?
| | Transforming Growth Factor beta1 | 5 | 2011 | 164 | 0.240 |
Why?
| | Mice, Nude | 4 | 2020 | 663 | 0.240 |
Why?
| | Matrix Metalloproteinases | 2 | 2011 | 90 | 0.230 |
Why?
| | Cell Transdifferentiation | 3 | 2010 | 32 | 0.220 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 176 | 0.210 |
Why?
| | Lipids | 1 | 2015 | 607 | 0.210 |
Why?
| | Nanoparticles | 1 | 2015 | 325 | 0.200 |
Why?
| | Skin | 1 | 2015 | 657 | 0.190 |
Why?
| | PAX3 Transcription Factor | 1 | 2020 | 12 | 0.190 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2020 | 18 | 0.190 |
Why?
| | Connective Tissue Growth Factor | 5 | 2017 | 21 | 0.190 |
Why?
| | Forkhead Box Protein O1 | 1 | 2020 | 15 | 0.190 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2020 | 13 | 0.190 |
Why?
| | Neoplasm Invasiveness | 5 | 2017 | 462 | 0.190 |
Why?
| | Mice, Inbred BALB C | 3 | 2020 | 1206 | 0.180 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 57 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 740 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2014 | 671 | 0.170 |
Why?
| | Cell Line, Tumor | 5 | 2020 | 2851 | 0.170 |
Why?
| | Ameloblastoma | 1 | 2008 | 5 | 0.170 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2020 | 181 | 0.160 |
Why?
| | Skin Neoplasms | 1 | 2015 | 762 | 0.160 |
Why?
| | Dihydropyridines | 1 | 2017 | 15 | 0.160 |
Why?
| | Tongue Neoplasms | 1 | 2007 | 21 | 0.160 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2017 | 24 | 0.150 |
Why?
| | Annexin A1 | 1 | 2017 | 2 | 0.150 |
Why?
| | Blotting, Western | 5 | 2017 | 1194 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 394 | 0.150 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 54 | 0.150 |
Why?
| | Paracrine Communication | 1 | 2007 | 57 | 0.150 |
Why?
| | Fibromatosis, Gingival | 2 | 2007 | 2 | 0.150 |
Why?
| | Retinal Pigment Epithelium | 1 | 2017 | 60 | 0.140 |
Why?
| | Bone Neoplasms | 1 | 2008 | 199 | 0.140 |
Why?
| | Transforming Growth Factor beta | 2 | 2007 | 462 | 0.140 |
Why?
| | Neovascularization, Physiologic | 1 | 2017 | 181 | 0.140 |
Why?
| | Cell Line | 3 | 2020 | 2707 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2015 | 77 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 317 | 0.130 |
Why?
| | Animals | 9 | 2020 | 33381 | 0.130 |
Why?
| | Multigene Family | 1 | 2015 | 200 | 0.130 |
Why?
| | Humans | 23 | 2020 | 118974 | 0.120 |
Why?
| | Gene Knockdown Techniques | 3 | 2020 | 311 | 0.120 |
Why?
| | Actins | 5 | 2011 | 404 | 0.120 |
Why?
| | Phenotype | 4 | 2020 | 3003 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2017 | 982 | 0.120 |
Why?
| | Down-Regulation | 4 | 2017 | 627 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2017 | 606 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 827 | 0.110 |
Why?
| | Cofilin 1 | 1 | 2012 | 5 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2015 | 307 | 0.110 |
Why?
| | Cell Movement | 1 | 2017 | 896 | 0.110 |
Why?
| | Apoptosis | 5 | 2017 | 2484 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 401 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1390 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2014 | 333 | 0.110 |
Why?
| | Muscle, Smooth | 3 | 2011 | 157 | 0.100 |
Why?
| | Mice | 6 | 2020 | 15520 | 0.090 |
Why?
| | Protein Phosphatase 2 | 1 | 2020 | 35 | 0.090 |
Why?
| | Retinoblastoma Protein | 1 | 2020 | 52 | 0.090 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 80 | 0.090 |
Why?
| | Ki-67 Antigen | 1 | 2020 | 108 | 0.090 |
Why?
| | Methylation | 1 | 2020 | 204 | 0.090 |
Why?
| | Drug Synergism | 1 | 2020 | 339 | 0.090 |
Why?
| | Cell Differentiation | 3 | 2020 | 1753 | 0.080 |
Why?
| | Gene Expression | 2 | 2017 | 1489 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1691 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 874 | 0.080 |
Why?
| | Phosphorylation | 2 | 2012 | 1633 | 0.080 |
Why?
| | Mitochondrial Dynamics | 1 | 2017 | 27 | 0.080 |
Why?
| | Smad2 Protein | 2 | 2011 | 39 | 0.080 |
Why?
| | Up-Regulation | 2 | 2017 | 872 | 0.070 |
Why?
| | Cell Cycle | 2 | 2017 | 550 | 0.070 |
Why?
| | Proteomics | 1 | 2012 | 876 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2020 | 649 | 0.070 |
Why?
| | NF-kappa B | 1 | 2020 | 670 | 0.070 |
Why?
| | Iontophoresis | 1 | 2015 | 13 | 0.070 |
Why?
| | Skin Absorption | 1 | 2015 | 12 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 681 | 0.070 |
Why?
| | Carcinogenesis | 1 | 2017 | 182 | 0.070 |
Why?
| | Collagen Type I | 2 | 2011 | 114 | 0.070 |
Why?
| | Administration, Topical | 1 | 2015 | 141 | 0.070 |
Why?
| | Male | 9 | 2020 | 57801 | 0.060 |
Why?
| | Cell Culture Techniques | 2 | 2011 | 356 | 0.060 |
Why?
| | Culture Media | 2 | 2017 | 163 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2007 | 736 | 0.060 |
Why?
| | Swine | 1 | 2015 | 730 | 0.060 |
Why?
| | Necrosis | 1 | 2014 | 230 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2014 | 410 | 0.060 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2012 | 2 | 0.060 |
Why?
| | Child | 2 | 2019 | 19129 | 0.050 |
Why?
| | Fluorometry | 1 | 2012 | 20 | 0.050 |
Why?
| | DNA Fragmentation | 1 | 2012 | 48 | 0.050 |
Why?
| | Caspase 9 | 1 | 2012 | 50 | 0.050 |
Why?
| | Cisplatin | 1 | 2014 | 271 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 87 | 0.050 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2012 | 40 | 0.050 |
Why?
| | Organelles | 1 | 2012 | 55 | 0.050 |
Why?
| | Immunoassay | 1 | 2012 | 101 | 0.050 |
Why?
| | Aged | 5 | 2020 | 19657 | 0.050 |
Why?
| | Antimetabolites | 1 | 2011 | 25 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2011 | 76 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 69 | 0.050 |
Why?
| | Caspase 3 | 1 | 2012 | 243 | 0.050 |
Why?
| | Adult | 6 | 2020 | 31512 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 127 | 0.050 |
Why?
| | Glutathione | 1 | 2012 | 324 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 195 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 10793 | 0.050 |
Why?
| | Membrane Microdomains | 1 | 2020 | 35 | 0.050 |
Why?
| | Anthracyclines | 1 | 2020 | 41 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1597 | 0.050 |
Why?
| | Female | 7 | 2020 | 61565 | 0.050 |
Why?
| | Prognosis | 2 | 2008 | 3443 | 0.050 |
Why?
| | Middle Aged | 5 | 2020 | 27617 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2012 | 420 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2020 | 305 | 0.040 |
Why?
| | Tretinoin | 1 | 2020 | 116 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2020 | 152 | 0.040 |
Why?
| | Transfection | 1 | 2011 | 888 | 0.040 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2008 | 30 | 0.040 |
Why?
| | Bone Marrow | 1 | 2020 | 255 | 0.040 |
Why?
| | Antioxidants | 1 | 2012 | 564 | 0.040 |
Why?
| | Mitochondrial Size | 1 | 2017 | 3 | 0.040 |
Why?
| | Cytoplasm | 1 | 2008 | 269 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 56 | 0.040 |
Why?
| | Genes, myc | 1 | 2017 | 46 | 0.040 |
Why?
| | Colony-Forming Units Assay | 1 | 2017 | 93 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2011 | 446 | 0.040 |
Why?
| | Tongue | 1 | 2007 | 73 | 0.040 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2017 | 39 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2445 | 0.040 |
Why?
| | Luciferases | 1 | 2017 | 143 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2011 | 1085 | 0.040 |
Why?
| | Luminescent Measurements | 1 | 2017 | 72 | 0.040 |
Why?
| | Heterografts | 1 | 2017 | 130 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 95 | 0.040 |
Why?
| | Acyltransferases | 1 | 2017 | 53 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 1267 | 0.040 |
Why?
| | Immediate-Early Proteins | 2 | 2007 | 55 | 0.040 |
Why?
| | Eye Diseases | 1 | 2017 | 77 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 2007 | 160 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 287 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 1158 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2012 | 1178 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 811 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 239 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 756 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2007 | 369 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1223 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 253 | 0.030 |
Why?
| | Signal Transduction | 2 | 2011 | 4709 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 870 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 465 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2011 | 2657 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 106 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2008 | 1059 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 332 | 0.030 |
Why?
| | Disease Progression | 1 | 2008 | 2490 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 1720 | 0.020 |
Why?
| | Adolescent | 2 | 2020 | 18480 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 681 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 1900 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 433 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 2566 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2007 | 6561 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2020 | 12978 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2006 | 1293 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5392 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2007 | 4077 | 0.010 |
Why?
|
|
Martin Sobral's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|